Pinetree Capital Ltd. Acquires Securities of Aptose Biosciences Inc.

TORONTO, CANADA--(Marketwired - Nov. 7, 2014) - Pinetree Capital Ltd. (TSX:PNP) announces that on November 6, 2014, it acquired ownership of 18,565 common shares ("Common Shares") of Aptose Biosciences Inc. ("Aptose") through the facilities of the Toronto Stock Exchange, representing approximately 0.2% of the total issued and outstanding common shares of Aptose as of November 6, 2014. As a result of this transaction, Pinetree and its joint actors collectively held, as at November 6, 2014, an aggregate of 1,473,333 common shares of Aptose, including the Common Shares, or approximately 12.7% of the total issued and outstanding common shares of Aptose as of November 6, 2014. Of these totals, Pinetree owns 855,000 common shares, including the Common Shares, directly, or approximately 7.4% of the total issued and outstanding common shares of Aptose as of November 6, 2014.

These transactions were made for investment purposes and Pinetree and its joint actors could increase or decrease their investment in Aptose depending on market conditions or any other relevant factor.

About Pinetree

Pinetree Capital Ltd. ("Pinetree") was incorporated under the laws of the Province of Ontario and its shares are publicly-traded on the Toronto Stock Exchange ("TSX") under the symbol "PNP". Pinetree is a diversified investment and merchant banking firm focused on the small cap market. Pinetree's investments are primarily in the following sectors: Precious Metals, Uranium and Technology. Pinetree's investment approach is to develop a macro view of a sector, build a position consistent with the view by identifying micro-cap opportunities within that sector, and devise an exit strategy designed to maximize our relative return in light of changing fundamentals and opportunities. Pinetree is recognized as a value added partner.